Nexalin Technology (NXL) Non-Current Debt (2021)
Nexalin Technology's (NXL) quarterly Non-Current Debt came in at $22916.0 in Q4 2021.
Nexalin Technology (NXL) Non-Current Debt (2021) Analysis & Trends
Nexalin Technology's Non-Current Debt history runs 1 years deep, the most recent figure standing at $22916.0 for Q4 2021.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $22916.0 in Q4 2021; TTM through Dec 2021 was $22916.0, a N/A change from a year earlier, with the FY2021 full-year figure at $22916.0, changed N/A from the prior year.
- Non-Current Debt steadied at $22916.0 in Q4 2021 per NXL's latest filing.
- Across five years, Non-Current Debt topped out at $22916.0 in Q4 2021 and bottomed at $22916.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 29.64 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.22 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 26.17 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 10.99 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 598.50 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.18 Bn |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 22,916.00 |